<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03527589</url>
  </required_header>
  <id_info>
    <org_study_id>PAE-P4-17-01</org_study_id>
    <nct_id>NCT03527589</nct_id>
  </id_info>
  <brief_title>Embosphere® PROstate Post Market Study</brief_title>
  <acronym>PROstate</acronym>
  <official_title>A Prospective Post Market Study of Patients With Symptomatic Benign Prostatic Hyperplasia Treated by Prostatic Artery Embolization With Embosphere® Microspheres</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merit Medical Systems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merit Medical Systems, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prostatic artery embolization with Embosphere Microspheres is a relatively new procedure. The&#xD;
      goal of this post market study is to evaluate long-term safety and effectiveness in a 'real&#xD;
      world' setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, open label post market study to evaluate the long-term safety and&#xD;
      effectiveness of prostatic artery embolization (PAE) using Embosphere Microspheres. Up to 500&#xD;
      patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH)&#xD;
      will be enrolled in this single arm post market study. All patients at sites who meet&#xD;
      eligibility criteria will be offered participation. Long term effectiveness of PAE on LUTS&#xD;
      will be evaluated by International Prostate Symptom Score (IPSS) at baseline, 3 months, 12&#xD;
      months, 24 months and 36 months. Safety will be assessed by evaluating device or&#xD;
      procedure-related adverse events at the same time points, plus at 4 weeks following&#xD;
      embolization. Erectile function will be assessed at baseline and 12 months by Sexual Health&#xD;
      Inventory for Men (SHIM) score. Additional treatments for refractory or recurrent LUTS due to&#xD;
      BPH post prostatic artery embolization will also be recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 16, 2018</start_date>
  <completion_date type="Anticipated">January 20, 2023</completion_date>
  <primary_completion_date type="Actual">January 26, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>36 Months</target_duration>
  <primary_outcome>
    <measure>Evaluate the long-term effectiveness of prostatic artery embolization (PAE) with Embosphere Microspheres as assessed by the International Prostate Symptom Score (IPSS).</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate IPSS after discontinuation of indwelling bladder catheter (IBC) post PAE.</measure>
    <time_frame>3, 24, 36 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate quality of life due to urinary symptoms after discontinuation of indwelling bladder catheter (IBC) post PAE using the I-PSS quality of life assessment index.</measure>
    <time_frame>3, 24, 36 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of device or procedure related adverse events post procedure.</measure>
    <time_frame>3, 12, 24, 36 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate frequency of indwelling bladder catheter (IBC) removal post PAE.</measure>
    <time_frame>3, 12, 24, 36 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical Success defined as successful embolization of the treated prostate gland.</measure>
    <time_frame>Day of PAE Procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of additional treatments for refractory or recurrent LUTS due to BPH post PAE.</measure>
    <time_frame>3, 12, 24, 36 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of change from baseline in erectile function post PAE using the Sexual Health Inventory for Men (SHIM).</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">499</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <condition>Lower Urinary Tract Symptoms</condition>
  <arm_group>
    <arm_group_label>Treated with Embosphere Microspheres</arm_group_label>
    <description>Patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) will be treated with Embosphere Microspheres (size of embolic determined at Investigator discretion).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prostate artery embolization</intervention_name>
    <description>Patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) will be treated with Embosphere Microspheres via prostate artery embolization.</description>
    <arm_group_label>Treated with Embosphere Microspheres</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Men with lower urinary tract sypmtoms (LUTS) due to benign prostatic hyperplasia (BPH)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient has signed informed consent&#xD;
&#xD;
          -  Patient age is 18 years or older at time of informed consent&#xD;
&#xD;
          -  Patient will undergo prostatic artery embolization with Embosphere Microspheres for&#xD;
             the treatment of symptomatic benign prostatic hyperplasia with lower urinary tract&#xD;
             symptoms&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient is unable or unwilling to provide follow-up information&#xD;
&#xD;
          -  Patient is undergoing prostatic artery embolization for reasons that do not include&#xD;
             symptomatic benign prostatic hyperplasia with lower urinary tract symptoms&#xD;
&#xD;
          -  Any other reason the investigator deems cause for exclusion&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only males can receive prostatic artery embolization</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>VA Long Beach Healthcare Systems</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Irvine Health</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami- Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Sacred Heart</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôspital Européan Georges Pompidou HEGP</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Croce e Carle Cuneo</name>
      <address>
        <city>Cuneo</city>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Niguarda Ca' Granda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Headington</city>
        <state>Oxford</state>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frimley Park Hospital</name>
      <address>
        <city>Camberley</city>
        <state>Surrey</state>
        <zip>GU16 7UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth and Christchurch Hospital</name>
      <address>
        <city>Bournemouth</city>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Berkshire Hospital</name>
      <address>
        <city>Reading</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 24, 2018</study_first_submitted>
  <study_first_submitted_qc>May 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2018</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostatic Artery Embolization</keyword>
  <keyword>Benign Prostatic Hyperplasia</keyword>
  <keyword>Lower Urinary Tract Symptoms</keyword>
  <keyword>PAE</keyword>
  <keyword>BPH</keyword>
  <keyword>LUTS</keyword>
  <keyword>Embolization</keyword>
  <keyword>Embolic</keyword>
  <keyword>Embosphere Microsphere</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

